How does semaglutide compare to other GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors in terms of efficacy and mechanisms of action on glycemic control, lipid metabolism, and cardiovascular outcomes in patients with type 2 diabetes?
CLC’s team, led by Ms. Sharon Benmayor, BS Biology & MSc Marine Environmental Science Stony Brook University, CLC’s Biology & ESS teacher, mentored and supervised our students Andreas Moutselos, Anastasia Pentidi, Davidoula Georgopoulou, Nickolas Saliveros, Maira Malik, Sophia Antoniades and Tony Wang to carry out a research project on semaglutide and type 2 diabetes.
This scientific literature review investigates the multifaceted impacts of semaglutide on glucose metabolism, lipid profiles, and cardiovascular health, comparing its efficacy and mechanisms of action with other GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors. Semaglutide, a GLP-1 receptor agonist, has shown significant promise in managing type 2 diabetes by improving glycemic control and promoting weight loss.
It explores how semaglutide facilitates HbA1c reduction, modulates triglyceride levels, and influences lipoprotein profiles, and examines factors that affect the drug’s efficacy, including insulin resistance, genetic variations, hormonal imbalances, gut microbiota composition, psychological and behavioral factors, metabolic adaptations, and concomitant medications.
Finally, the mechanisms by which semaglutide indirectly supports muscle protein synthesis, energy expenditure, and appetite regulation, contributing to its overall efficacy in weight management and metabolic health are discussed.
